ERBB2 and breast cancer: However, studies on somatic mutations and tumor microenvironment wherein data analyses are performed by molecular subtypes have shown remarkable heterogeneity [11–13], with the highest immunogenic potential being ascribed to triple negative breast cancer (TNBC) and HER2+ BC among BC subtypes [14].